StreetInsider.com News Articles

Form SCHEDULE 13D MAXCYTE, INC. Filed by: RIVER GLOBAL INVESTORS LLP

Thu, 14 May 2026 09:45:00 -0400

si-local-file:///var/storage/secattach/20260514/26491499.html

Form SCHEDULE 13D MAXCYTE, INC. Filed by: RIVER GLOBAL INVESTORS LLP

Thu, 14 May 2026 09:45:00 -0400

si-local-file:///var/storage/secattach/20260514/26491499.html

Form 10-Q MAXCYTE, INC. For: Mar 31

Wed, 13 May 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260513/26486793.html

Form 10-Q MAXCYTE, INC. For: Mar 31

Wed, 13 May 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260513/26486793.html

MaxCyte, Inc. (MXCT) Tops Q1 EPS by 4c

Tue, 12 May 2026 16:49:58 -0400

MaxCyte, Inc. (NASDAQ: MXCT) reported Q1 EPS of ($0.04), $0.04 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $9.7 million versus the consensus estimate of $7.3 million.

For earnings history and earnings-related data on MaxCyte, Inc. (MXCT) click here.

Form 8-K MAXCYTE, INC. For: May 12

Tue, 12 May 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260512/26478001.html

Form 8-K MAXCYTE, INC. For: May 12

Tue, 12 May 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260512/26478001.html

MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance

Tue, 12 May 2026 16:05:00 -0400

First quarter 2026 total revenue of $9.7 million, including $6.2 million of core revenue and $3.4 million of SPL Program-related revenue

Reiterates 2026 revenue guidance of $30-32 million; with Core revenue of $25-27 million and Strategic Platform License (SPL) Program-related of $5 million

MaxCyte’s Board authorized a $10 million share repurchase program

ROCKVILLE, Md., May 12, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its first quarter ended March

MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance

Tue, 12 May 2026 16:05:00 -0400

First quarter 2026 total revenue of $9.7 million, including $6.2 million of core revenue and $3.4 million of SPL Program-related revenue

Reiterates 2026 revenue guidance of $30-32 million; with Core revenue of $25-27 million and Strategic Platform License (SPL) Program-related of $5 million

MaxCyte’s Board authorized a $10 million share repurchase program

Form ARS MAXCYTE, INC. For: Dec 31

Wed, 29 Apr 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260429/26396272.html

Form ARS MAXCYTE, INC. For: Dec 31

Wed, 29 Apr 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260429/26396272.html

Form DEFA14A MAXCYTE, INC.

Wed, 29 Apr 2026 16:48:00 -0400

si-local-file:///var/storage/secattach/20260429/26396255.html

Form DEFA14A MAXCYTE, INC.

Wed, 29 Apr 2026 16:48:00 -0400

si-local-file:///var/storage/secattach/20260429/26396255.html

Form DEF 14A MAXCYTE, INC. For: Jun 17

Wed, 29 Apr 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260429/26396198.html

Form DEF 14A MAXCYTE, INC. For: Jun 17

Wed, 29 Apr 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260429/26396198.html

MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026

Wed, 29 Apr 2026 16:05:00 -0400

ROCKVILLE, Md., April 29, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the first quarter 2026 after the U.S. market close on Tuesday, May 12^th, 2026. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.

Earnings Conference Call Details
Investors interested in listening to the conference call are required to register online. It is recommended to register at

MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026

Wed, 29 Apr 2026 16:05:00 -0400

Earnings Conference Call Details
Investors interested in listening to the conference call are required to register online. It is recommended to register at

Form 4 MAXCYTE, INC. For: Apr 15 Filed by: Ahuja Parmeet

Fri, 17 Apr 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260417/26330799.html

Form 4 MAXCYTE, INC. For: Apr 15 Filed by: Ahuja Parmeet

Fri, 17 Apr 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260417/26330799.html

Form S-8 MAXCYTE, INC.

Wed, 15 Apr 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260415/26318714.html

Form S-8 MAXCYTE, INC.

Wed, 15 Apr 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260415/26318714.html

Form 4 MAXCYTE, INC. For: Mar 30 Filed by: Ahuja Parmeet

Fri, 10 Apr 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260410/26300555.html

Form 4 MAXCYTE, INC. For: Mar 30 Filed by: Ahuja Parmeet

Fri, 10 Apr 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260410/26300555.html

Form 3 MAXCYTE, INC. For: Mar 30 Filed by: Ahuja Parmeet

Fri, 10 Apr 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260410/26300535.html

Form 3 MAXCYTE, INC. For: Mar 30 Filed by: Ahuja Parmeet

Fri, 10 Apr 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260410/26300535.html